2023
Zillow MD: Do housing prices predict cancer survival?
Dinan M, Wheeler S. Zillow MD: Do housing prices predict cancer survival? JNCI Cancer Spectrum 2023, 7: pkad086. PMID: 37965909, PMCID: PMC10646759, DOI: 10.1093/jncics/pkad086.Peer-Reviewed Original ResearchClinician Perspectives on Managing Chronic Pain After Curative-Intent Cancer Treatment
Check D, Jones K, Fish L, Dinan M, Dunbar T, Farley S, Ma J, Merlin J, O'Regan A, Oeffinger K. Clinician Perspectives on Managing Chronic Pain After Curative-Intent Cancer Treatment. JCO Oncology Practice 2023, 19: e484-e491. PMID: 36595729, PMCID: PMC10530392, DOI: 10.1200/op.22.00410.Peer-Reviewed Original ResearchConceptsChronic painCancer survivorsClinician experienceLong-term opioid therapyMultimodal pain careCurative-intent treatmentBehavioral health servicesAcademic medical centerOpioid therapyOpioid managementActive treatmentPain careHighlights unmetHigh prevalenceClinician's perspectiveMedical CenterMost cliniciansPainMultidisciplinary teamHealth servicesPsychosocial stressorsPain monitoringCliniciansCancer treatmentSurvivors
2022
Concurrent prescribing of opioids with other sedating medications after cancer diagnosis: a population-level analysis
Check D, Baggett C, Kim K, Merlin J, Oeffinger K, Winn A, Roberts M, Robinson T, Dinan M. Concurrent prescribing of opioids with other sedating medications after cancer diagnosis: a population-level analysis. Supportive Care In Cancer 2022, 30: 9781-9791. PMID: 36396793, DOI: 10.1007/s00520-022-07439-y.Peer-Reviewed Original ResearchMeSH KeywordsAgedAnalgesics, OpioidBenzodiazepinesHumansMedicareNeoplasmsRetrospective StudiesUnited StatesConceptsConcurrent prescribingSedating medicationsPatient characteristicsMedication-related eventsRetrospective cohort studyNon-metastatic cancerPopulation-based assessmentCancer registry dataMental health conditionsSubstance use disordersPrivate insurance claimsConcurrent prescriptionsCohort studyHispanic patientsSymptom managementRelative riskRegistry dataGabapentinoidsOpioidsPrescribingUse disordersPatientsPoisson regressionPrior useMedicationsRacial and Ethnic Variation in COVID-19 Vaccination Uptake Among Medicare Beneficiaries with Cancer History
Poghosyan H, Dinan MA, Tamamyan G, Nelson L, Jeon S. Racial and Ethnic Variation in COVID-19 Vaccination Uptake Among Medicare Beneficiaries with Cancer History. Journal Of Racial And Ethnic Health Disparities 2022, 10: 2354-2362. PMID: 36149576, PMCID: PMC9510246, DOI: 10.1007/s40615-022-01415-2.Peer-Reviewed Original ResearchConceptsNon-Hispanic white beneficiariesCancer historyVaccine doseMedicare beneficiariesWhite beneficiariesVaccine uptakeHispanic beneficiariesMultivariable logistic regression analysisCOVID-19 vaccination uptakeSelf-reported cancer historyCOVID-19 vaccine uptakeSelf-reported receiptCOVID-19 vaccination ratesLogistic regression analysisNon-Hispanic blacksSelf-reported raceUnvaccinated beneficiariesVaccination uptakeVaccine dosesVaccination ratesVaccine confidenceVaccine availabilitySupplement surveyCross-sectional dataEthnic variation
2021
Low-touch, team-based care for co-morbidity management in cancer patients: the ONE TEAM randomized controlled trial
Zullig LL, Shahsahebi M, Neely B, Hyslop T, Avecilla RAV, Griffin BM, Clayton-Stiglbauer K, Coles T, Owen L, Reeve BB, Shah K, Shelby RA, Sutton L, Dinan MA, Zafar SY, Shah NP, Dent S, Oeffinger KC. Low-touch, team-based care for co-morbidity management in cancer patients: the ONE TEAM randomized controlled trial. BMC Primary Care 2021, 22: 234. PMID: 34794388, PMCID: PMC8600877, DOI: 10.1186/s12875-021-01569-8.Peer-Reviewed Original ResearchConceptsPrimary care providersCancer survivorsCardiovascular diseaseMedication adherenceCancer specialistsCare providersPrimary care clinic levelInformation Set (HEDIS) quality measuresPharmacy refill dataPrimary care clinicsHealthcare Effectiveness DataHistory of cancerPrimary care physiciansProvider-level interventionsCo-morbidity managementPatient-provider communicationPrimary care teamsBlood pressure measurementsTeam-based careEducation-only controlSequential multiple assignmentCVD comorbidityRefill dataCare clinicsCare physiciansOpioid Prescribing and Use Among Cancer Survivors: A Mapping Review of Observational and Intervention Studies
Check DK, Avecilla R, Mills C, Dinan MA, Kamal AH, Murphy B, Rezk S, Winn A, Oeffinger K. Opioid Prescribing and Use Among Cancer Survivors: A Mapping Review of Observational and Intervention Studies. Journal Of Pain And Symptom Management 2021, 63: e397-e417. PMID: 34748896, DOI: 10.1016/j.jpainsymman.2021.10.015.Peer-Reviewed Original ResearchConceptsOpioid useOpioid prescribingCancer survivorsHigh-risk opioid prescribingLong-term opioid useEvidence synthesisContinued opioid useLate opioid usePersistent opioid useProlonged opioid useChronic opioid useUse of opioidsHigh-risk medicationsOpioid use outcomesFull-text reviewTitles/abstractsOpioid misuseChronic useInclusion criteriaExclusion criteriaIntervention studiesInterventional researchPrescribingProlonged useStudy designPredictors of Chronic Opioid Use: A Population-Level Analysis of North Carolina Cancer Survivors Using Multi-Payer Claims
Check DK, Baggett C, Kim K, Roberts AW, Roberts MC, Robinson T, Oeffinger KC, Dinan MA. Predictors of Chronic Opioid Use: A Population-Level Analysis of North Carolina Cancer Survivors Using Multi-Payer Claims. Journal Of The National Cancer Institute 2021, 113: 1581-1589. PMID: 33881543, PMCID: PMC8562975, DOI: 10.1093/jnci/djab082.Peer-Reviewed Original ResearchConceptsChronic opioid useChronic opioid therapyOpioid useCancer survivorsOpioid therapyBaseline depressionLong-term pain managementSubstance useRetrospective cohort studyPopulation-based studyCancer registry dataLow-income survivorsCohort studyPatient characteristicsPain managementActive treatmentNonmetastatic cancerChronic useInsurance statusRelative riskRegistry dataOpioidsPoisson regressionYounger ageAge groupsReporting of Study Participant Demographic Characteristics and Demographic Representation in Premarketing and Postmarketing Studies of Novel Cancer Therapeutics
Varma T, Wallach JD, Miller JE, Schnabel D, Skydel JJ, Zhang AD, Dinan MA, Ross JS, Gross CP. Reporting of Study Participant Demographic Characteristics and Demographic Representation in Premarketing and Postmarketing Studies of Novel Cancer Therapeutics. JAMA Network Open 2021, 4: e217063. PMID: 33877309, PMCID: PMC8058642, DOI: 10.1001/jamanetworkopen.2021.7063.Peer-Reviewed Original ResearchConceptsNovel cancer therapeuticsPostmarketing studyBlack patientsCancer therapeuticsDemographic dataOlder adultsUS cancer populationUS Cancer StatisticsCross-sectional studyRace/ethnicityParticipants' demographic characteristicsPercentage of trialsPatient sexCancer populationClinical studiesCancer statisticsMAIN OUTCOMEDrug AdministrationFDA approvalStudy participantsCancer typesDemographic characteristicsDemographic informationStudy samplePatients
2018
Advanced imaging and hospice use in end-of-life cancer care
Dinan MA, Curtis LH, Setoguchi S, Cheung WY. Advanced imaging and hospice use in end-of-life cancer care. Supportive Care In Cancer 2018, 26: 3619-3625. PMID: 29728843, DOI: 10.1007/s00520-018-4223-0.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overBlack or African AmericanBreast NeoplasmsColorectal NeoplasmsComorbidityDiagnostic ImagingFemaleHospice CareHospicesHumansLung NeoplasmsMaleMedicareMiddle AgedNeoplasmsOutcome Assessment, Health CareProstatic NeoplasmsReferral and ConsultationRetrospective StudiesSEER ProgramTerminal CareUnited StatesConceptsHospital referral regionsHospice enrollmentComputerized tomographyHospice useLife careReferral regionsAdvanced imagingPopulation-based retrospective studyHigh rateLate hospice enrollmentLife cancer careMultivariable logistic regressionSEER-Medicare dataMagnetic resonance imagingPositron emission tomographyEnd of lifeGreater comorbidityReal-world practiceAggressive endBlack patientsMultivariable analysisRetrospective studyResultsA totalStudy criteriaCancer care
2014
Exploring variation in care: alternative conceptual models.
Dinan MA, Schulman KA. Exploring variation in care: alternative conceptual models. Annals Of Internal Medicine 2014, 161: 835-6. PMID: 25437412, DOI: 10.7326/m14-2382.Peer-Reviewed Original Research
2010
Changes in the Use and Costs of Diagnostic Imaging Among Medicare Beneficiaries With Cancer, 1999-2006
Dinan MA, Curtis LH, Hammill BG, Patz EF, Abernethy AP, Shea AM, Schulman KA. Changes in the Use and Costs of Diagnostic Imaging Among Medicare Beneficiaries With Cancer, 1999-2006. JAMA 2010, 303: 1625-1631. PMID: 20424253, DOI: 10.1001/jama.2010.460.Peer-Reviewed Original ResearchConceptsNon-Hodgkin lymphomaLung cancerMedicare beneficiariesBreast cancerCancer typesColorectal cancerProstate cancerImaging costsPositron emission tomography scanIncident breast cancerYear of diagnosisEmission tomography scanBone density studiesMean total costMagnetic resonance imagingPositron emission tomographyBone scanTreatment patternsIncident casesCancer careHalf of beneficiariesTomography scanUS CentersMean annual increaseResonance imagingSplicerAV: a tool for mining microarray expression data for changes in RNA processing
Robinson TJ, Dinan MA, Dewhirst M, Garcia-Blanco MA, Pearson JL. SplicerAV: a tool for mining microarray expression data for changes in RNA processing. BMC Bioinformatics 2010, 11: 108. PMID: 20184770, PMCID: PMC2838864, DOI: 10.1186/1471-2105-11-108.Peer-Reviewed Original ResearchConceptsIsoform changesMRNA processingGuanyl nucleotide exchange factorMicroarray datasetsMRNA processing factorsTranscript isoform abundanceAlternative mRNA processingHG-U133Expression of HRASUnknown mechanismMicroarray expression dataHuman mammary epithelial cellsGene expression microarraysMammary epithelial cellsRNA processingExchange factorBreast cancer microarray datasetsAffymetrix HG-U133Alternative mRNABreast tumorsEGFR activationGene expressionExpression microarraysCancer microarray datasetsSpecific expression